Phathom Pharmaceuticals Announces Investor Conference Participation
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a biopharmaceutical company dedicated to creating and commercializing groundbreaking therapies for gastrointestinal diseases, has made an exciting announcement regarding its upcoming engagements with investors. The company's management team is set to participate in multiple investor conferences slated for the coming months, allowing them to connect directly with stakeholders and present their innovative vision for addressing GI disorders.
Highlights of Upcoming Conferences
Phathom will be prominently featured in several key industry events. These conferences provide a platform for the company to showcase its pipeline and engage in one-on-one discussions with investors, health care professionals, and other important stakeholders.
Guggenheim’s Inaugural Healthcare Innovation Conference
One of the first major appearances will be at Guggenheim’s inaugural Healthcare Innovation Conference. This event will take place on a date in November, where Phathom's management will engage in various one-on-one meetings throughout the conference. Participants can expect insightful dialogues on the company's future innovations and strategies.
Stifel 2024 Healthcare Conference
Another significant event is the Stifel 2024 Healthcare Conference scheduled for mid-November. Here, the Phathom team will also facilitate one-on-one interactions, enabling detailed discussions about their pioneering treatments.
International Presence at Jefferies London Healthcare Conference
The company’s reach extends internationally, with participation confirmed in the Jefferies London Healthcare Conference. This event highlights Phathom's commitment to sharing its vision and updates, offering yet another opportunity for face-to-face discussions with global investors.
Engagement at Evercore HealthCONx Conference
Wrapping up their conference engagements, Phathom will be part of the Evercore HealthCONx Conference in early December. This event promises to be an impactful platform for disseminating valuable information about their ongoing projects and future plans.
About Phathom Pharmaceuticals and Its Innovative Therapies
At the core of Phathom Pharmaceuticals' mission is the development and commercialization of novel treatments intended to benefit patients suffering from gastrointestinal illnesses. The company's flagship product, VOQUEZNA, is a first-in-class potassium-competitive acid blocker (PCAB) designed to address conditions such as heartburn related to Non-Erosive GERD and more severe gastrointestinal diseases.
Exploring the Impact of VOQUEZNA
Currently marketed as VOQUEZNA tablets, this innovative treatment aids patients in managing heartburn associated with GERD effectively. It works not only for the healing and maintenance of Erosive GERD but also provides relief from H. pylori infections through specialized treatment pak combinations like VOQUEZNA DUAL PAK® and VOQUEZNA TRIPLE PAK®.
Connecting with Phathom Pharmaceuticals
For those interested in attending the live webcasts of these investor conferences or exploring archived recordings, details are accessible through Phathom Pharmaceuticals’ official website. They have made it easy for stakeholders to stay informed by visiting the News & Events section online.
Media and Investor Relations Contacts
Phathom Pharmaceuticals encourages inquiries from media representatives and investors. The main media contact is Nick Benedetto, reachable at 1-877-742-8466 or via email. Investors can connect with Eric Sciorilli at the same phone number to discuss investment opportunities and insights.
Frequently Asked Questions
What is Phathom Pharmaceuticals known for?
Phathom Pharmaceuticals focuses on developing innovative treatments specifically for gastrointestinal diseases, particularly through its flagship product VOQUEZNA.
When are the upcoming investor conferences?
The company is participating in several conferences in November and December, including major events hosted by Guggenheim and Stifel.
How can I access the investor conference webcasts?
Webcasts and archived recordings can be found on the Phathom Pharmaceuticals website under their News & Events section.
What innovative products does Phathom offer?
Phathom offers VOQUEZNA, a first-in-class PCAB used for treating heartburn and Erosive GERD, along with adjunctive therapies in combination packs.
Who should I contact for media inquiries?
Media inquiries should be directed to Nick Benedetto, who can be reached at 1-877-742-8466 or through email for more information.